Basic Information
| VGSC-DB ID | NA4998 | |
|---|---|---|
| PubChem CID | 127047988 | |
| IUPAC Name | (3S)-3-amino-4-[[(1R,4S,10S,13S,16S,19S,22S,25R,30R,33S,36S,39S,42S,45S,48S,51R,54S,57S,60S,63S,69S,72R,77R,80S,86S,89S,92S,95S)-30-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-22,36,95-tris(4-aminobutyl)-16,60-bis(2-amino-2-oxoethyl)-86-benzyl-4-[(2S)-butan-2-yl]-45,54,69,92-tetrakis(3-carbamimidamidopropyl)-13,19-bis(carboxymethyl)-42-[(1R)-1-hydroxyethyl]-48-(hydroxymethyl)-39-(1H-imidazol-5-ylmethyl)-33-(1H-indol-3-ylmethyl)-57,80-bis(2-methylpropyl)-89-(2-methylsulfanylethyl)-2,3a,5,11,14,17,20,23,32,35,38,41,44,47,50,53,56,59,62,68,71,78,81,84,87,90,93,96-octacosaoxo-a,27,28,74,75,99-hexathia-2a,3,6,12,15,18,21,24,31,34,37,40,43,46,49,52,55,58,61,67,70,79,82,85,88,91,94,97-octacosazapentacyclo[49.46.4.225,72.06,10.063,67]trihectan-77-yl]amino]-4-oxobutanoic acid | |
| Molecular Formula | C177H274N56O45S7 |
|
| Molecular Weight | 4131.0g/mol | |
| IC50/EC50* (nM) | 60 | |
| Target | Nav1.7 | |
| Binding Site | VSDII | |
| Organism | Human | |
| UniProt Name | SCN9A_HUMAN | |
| UniProt ID | Q15858 | |
| SMILES | CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N2)NC(=O)[C@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(N)=O)C(C)C)NC(=O)[C@H](Cc2c[nH]c4ccccc24)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC3=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]2CCCN2C1=O | |
| Category | Toxins and derivatives | |
| InChI | InChI=1S/C177H274N56O45S7/c1-11-92(8)139-173(278)233-64-33-49-131(233)169(274)220-122(77-137(244)245)159(264)217-119(74-132(183)237)156(261)218-121(76-136(242)243)158(263)206-106(43-23-27-58-181)148(253)225-128-86-284-281-83-125(162(267)209-104(41-21-25-56-179)145(250)215-116(70-96-50-52-99(236)53-51-96)160(265)229-138(91(6)7)170(275)212-112(141(185)246)68-94-34-14-12-15-35-94)227-154(259)117(71-97-78-199-102-39-19-18-38-100(97)102)216-146(251)103(40-20-24-55-178)205-155(260)118(72-98-79-194-88-201-98)221-171(276)140(93(9)235)231-151(256)109(46-30-61-197-176(190)191)208-161(266)123(81-234)222-165(270)127-85-283-285-87-129(167(272)230-139)226-147(252)105(42-22-26-57-180)203-144(249)107(44-28-59-195-174(186)187)204-150(255)110(54-65-279-10)210-153(258)115(69-95-36-16-13-17-37-95)202-134(239)80-200-143(248)113(66-89(2)3)213-164(269)124(223-142(247)101(182)73-135(240)241)82-280-282-84-126(228-166(128)271)163(268)211-111(47-31-62-198-177(192)193)172(277)232-63-32-48-130(232)168(273)219-120(75-133(184)238)157(262)214-114(67-90(4)5)152(257)207-108(149(254)224-127)45-29-60-196-175(188)189/h12-19,34-39,50-53,78-79,88-93,101,103-131,138-140,199,234-236H,11,20-33,40-49,54-77,80-87,178-182H2,1-10H3,(H2,183,237)(H2,184,238)(H2,185,246)(H,194,201)(H,200,248)(H,202,239)(H,203,249)(H,204,255)(H,205,260)(H,206,263)(H,207,257)(H,208,266)(H,209,267)(H,210,258)(H,211,268)(H,212,275)(H,213,269)(H,214,262)(H,215,250)(H,216,251)(H,217,264)(H,218,261)(H,219,273)(H,220,274)(H,221,276)(H,222,270)(H,223,247)(H,224,254)(H,225,253)(H,226,252)(H,227,259)(H,228,271)(H,229,265)(H,230,272)(H,231,256)(H,240,241)(H,242,243)(H,244,245)(H4,186,187,195)(H4,188,189,196)(H4,190,191,197)(H4,192,193,198)/t92-,93+,101-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,138-,139-,140-/m0/s1 | |
| InChI Key | UGOYONMBZFCBPL-WFCNDGJPSA-N | |
| Article DOI | 10.1021/acs.jmedchem.5b01947 | |
| PMID | 26890998 | |
| Authors | Murray, JK; Long, J; Zou, A; Ligutti, J; Andrews, KL; Poppe, L; Biswas, K; Moyer, BD; McDonough, SI; Miranda, LP | |
| Institution | Amgen Inc | |
Calculated Properties
| Heavy Atom Count | 285 | Computed by RDKit |
|---|---|---|
| Ring Count | 11 | Computed by RDKit |
| Hydrogen Bond Acceptor Count | 59 | Computed by RDKit |
| Hydrogen Bond Donor Count | 59 | Computed by RDKit |
| Rotatable Bond Count | 75 | Computed by RDKit |
| logP | -4.17 | Computed by ADMETlab2.0 |
| logS | 0.99 | Computed by ADMETlab2.0 |
| logD | -1.35 | Computed by ADMETlab2.0 |